AP Biosciences Inc
TWO: 6945.TWO0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- Taipei Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Jeng-Horng Her
- Employees
- 37
- Headquarters
- Taipei City, Taiwan
- IPO year
- 2023
- Market cap
- NT$14.7B
- Website
- https://www.apbioinc.com
Loading 6945…
Loading profile data…Frequently asked questions about 6945
What does AP Biosciences Inc (6945.TWO) do?
AP Biosciences Inc, a clinical-stage biopharmaceutical company, researches and develops bispecific antibody drugs for unmet medical needs. It develops IBI302 that is in phase III clinical trials for the treatment of neovascular age-related macular degeneration; AP505 that is in phase I clinical trials for treating solid tumors; AP203 that is in...
Where does 6945.TWO trade?
AP Biosciences Inc (6945.TWO) trades on the Taipei Exchange.
What sector is 6945.TWO in?
AP Biosciences Inc (6945.TWO) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of AP Biosciences Inc?
Jeng-Horng Her is the chief executive officer of AP Biosciences Inc (6945.TWO).
Where is AP Biosciences Inc headquartered?
AP Biosciences Inc is headquartered in Taiwan.
Does 6945.TWO pay a dividend?
AP Biosciences Inc (6945.TWO) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did 6945.TWO go public?
AP Biosciences Inc (6945.TWO) completed its initial public offering in 2023.